Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

bitopertin

Roche Basel Switzerland

Roche moving closer to approval of Spark takeover; report

Antitrust authorities in both US and UK look likely to end delay

- PMLiVE

Seattle Genetics preps filing next year for oral HER2 drug

Company has positive phase 3 data to support filings

- PMLiVE

Roche eyes filings for Tecentriq/Avastin combo in liver cancer

Another important milestone for Roche's Tecentriq plans

Roche Basel Switzerland

Roche scores another FDA approval for Xofluza

Expands use to patients at high risk of flu-related complications

Roche Basel Switzerland

Roche reports continued growth in Q3, despite biosimilar competition

Spark acquisition expected to complete this year

- PMLiVE

NICE turns down Roche’s Tecentriq for triple-negative breast cancer

Will also not be included in the Cancer Drugs Fund

- PMLiVE

Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval

Will likely face competition soon from rival Rozlytrek

Roche - Basel

Roche wins FDA breakthrough for Gazyva in lupus nephritis

Drug originally approved as a lymphoma treatment

- PMLiVE

Roche preps filings for Herceptin/Perjeta combination

Potential defence against biosimilar competition

Roche Basel Switzerland

Roche presents new data in NMOSD, could challenge Alexion’s Soliris

Reduced risk of relapse by 55%

AstraZeneca AZ

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

New data shows improvement in overall survival

Roche Basel Switzerland

Roche scores EU approval twice for Tecentriq in lung cancer

Carves out space in a market dominated by MSD's Keytruda

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links